How Does Imatinib Work? — The BCR-ABL and KIT Inhibitor Explained

In CML, a proportion of patients who take imatinib consistently for years reach a point where the BCR-ABL signal is undetectable on sensitive blood tests — a deep molecular response. The gene is still present in a small number of cells, but the disease is under effective control. ESMO and NCCN guidance does not use the word cure for CML managed with imatinib. In GIST, imatinib is intended to control tumour growth in patients who respond, for as long as the drug is taken and the tumour remains sensitive to it.

For some patients with CML who have achieved a deep molecular response sustained over a number of years, stopping imatinib and remaining in remission — called treatment-free remission — is possible. It is not a universal outcome, and it is not something to attempt without your oncologist's guidance, because BCR-ABL monitoring must continue closely after stopping. If the signal returns, restarting is effective in most cases. The decision is based on your specific response data and how long that response has been sustained, not on a general rule.

Generic imatinib must meet the same bioequivalence standards as the original branded version — meaning it delivers the same amount of active drug to the bloodstream within the same timeframe. In India, CDSCO regulates generic medicines using these standards. Several locally manufactured generics are widely used. If you are switched from one version to another and notice a change in how you feel or in your blood test results, tell your team. A clinically significant difference is uncommon, but it is worth documenting if you experience one.

Yes. Resistance can develop, most commonly through mutations in the BCR-ABL gene that change the shape of the pocket imatinib fits into. Your team monitors for this through regular blood tests measuring the BCR-ABL signal in your blood. Rising levels are the earliest sign that the response is changing. If resistance develops, second-generation tyrosine kinase inhibitors — which target BCR-ABL differently — are available and are effective for many of the common resistance mutations. This is one of the main reasons regular monitoring appointments are not optional.

Yes. For minor dental work, imatinib does not usually need to be stopped, but your dentist should know you are taking it because it can affect bleeding. For surgery, your oncologist and surgeon need to discuss the timing together — imatinib affects wound healing in some patients, and the decision about pausing it must be made jointly. Never stop imatinib on your own before a procedure. The same applies to any new medicine: common drugs including certain antibiotics, antifungals, and anticonvulsants interact with imatinib through shared liver enzymes and can change how much drug is in your blood.

Imatinib is not recommended during pregnancy. Studies showed effects on foetal development, and the drug is present in breast milk. If you are of childbearing age, your team will discuss contraception with you before you start. If you become pregnant while on imatinib, contact your oncologist immediately — stopping abruptly carries its own risks, and managing CML or GIST during pregnancy requires specialist input. Men taking imatinib are generally advised to discuss fertility preservation with their team before starting treatment, as the evidence on paternal exposure is less established than for maternal.